General Pharmacology Practice Questions

Q: Which of the following statements is true about atosiban?

is an oxytocin receptor antagonist. ***is an oxytocin receptor antagonist*** - **Atosiban** works by competitively binding to **oxytocin receptors** in the myometrium, thereby preventing oxytocin from stimulating uterine contractions. - This action makes it effective in delaying **preterm labor** by reducing the frequency and intensity of contractions. - Atosiban is classified as a **tocolytic drug** specifically because of its oxytocin receptor antagonism. *is least effective in inhibiting preterm uterine contractions* - **Atosiban** is an **effective tocolytic** used to delay preterm labor, making this statement incorrect. - Studies show it can prolong pregnancy for several days, allowing for the administration of **corticosteroids** for fetal lung maturation. *is a progesterone receptor antagonist* - **Atosiban** specifically targets **oxytocin receptors**, not progesterone receptors. - Progesterone receptor antagonists (e.g., **mifepristone**) would induce labor rather than suppress it. *acts primarily on beta-adrenergic receptors* - **Atosiban** does not act on beta-adrenergic receptors; it is an **oxytocin receptor antagonist**. - Beta-adrenergic agonists like **ritodrine** and **terbutaline** are different tocolytics that work by relaxing uterine smooth muscle through beta-2 receptor stimulation.

Q: What is the classification of Sumatriptan?

5HT 1B/1D agonist. ***5HT 1B/1D agonist*** - Sumatriptan is a **selective serotonin receptor agonist**, specifically targeting the **5-HT1B** and **5-HT1D** receptor subtypes. - This is the **precise pharmacological classification** of triptans used in acute migraine treatment. - Agonism at **5-HT1B receptors** causes **vasoconstriction** of dilated cranial blood vessels. - Agonism at **5-HT1D receptors** inhibits the release of **pro-inflammatory neuropeptides** (CGRP, substance P) from trigeminal nerve endings. - This specific classification distinguishes sumatriptan from non-selective serotonin agonists. *5HT 1 agonist* - While technically not incorrect, this classification is **too broad and imprecise** for pharmacological purposes. - A general "5-HT1 agonist" could theoretically include activity at 5-HT1A, 1B, 1D, 1E, and 1F receptors. - Sumatriptan has **minimal affinity** for 5-HT1A receptors and its therapeutic effect is specifically due to 5-HT1B/1D activity. - In medical literature and standard pharmacology texts, triptans are classified as **5-HT1B/1D agonists**, not general 5-HT1 agonists. *5HT 1D antagonist* - An **antagonist** blocks receptor activity rather than activating it. - This would **worsen** migraine symptoms by preventing the therapeutic effects of endogenous serotonin. - There are no established antimigraine drugs that act as 5-HT1D antagonists. *5HT 1A antagonist* - 5-HT1A receptors are primarily involved in **mood regulation, anxiety, and sleep**, not acute migraine pathophysiology. - Sumatriptan has minimal activity at 5-HT1A receptors. - Antagonism at this receptor would not provide antimigraine effects and is unrelated to sumatriptan's mechanism.

Q: Hypercalcemia is caused by all except:

Loop diuretics. Hypercalcemia is caused by all except: ***Loop diuretics*** - **Loop diuretics** promote the urinary excretion of calcium by inhibiting the reabsorption of calcium in the thick ascending limb of the loop of Henle [3]. - This effect leads to a **decrease** in serum calcium levels and thus do not cause hypercalcemia. [3] *Lithium* - **Lithium** can cause hypercalcemia by increasing the set point for calcium sensing in the parathyroid glands, leading to increased parathyroid hormone (PTH) secretion. - This results in a mild, chronic hypercalcemia, often in the context of **secondary hyperparathyroidism**. *Vitamin D intoxication* - **Vitamin D intoxication** leads to excessive absorption of calcium from the gut and increased bone resorption, both contributing to hypercalcemia [1]. - High levels of vitamin D cause hypercalcemia that **suppresses PTH secretion** through negative feedback, resulting in hypercalcemia with inappropriately low PTH levels. *Thiazides* - **Thiazide diuretics** can cause mild hypercalcemia by increasing renal tubular reabsorption of calcium [2]. - They enhance calcium reabsorption in the **distal convoluted tubule**, leading to a slight elevation in serum calcium [2], [3].

Q: Which one of the following drugs does not interfere with folic acid metabolism?

Gabapentin. ***Gabapentin*** - **Gabapentin** is an anticonvulsant that primarily exerts its effects by modulating activity at voltage-gated calcium channels; it does **not interfere with folic acid metabolism**. - Its mechanism of action is distinct from other antiepileptic drugs that are known to cause folate deficiency. *Phenobarbitone* - **Phenobarbitone** is an antiepileptic drug that belongs to the barbiturate class and is known to be an **inducer of hepatic microsomal enzymes**. - This enzyme induction can **increase the metabolism of folic acid**, leading to its depletion and potentially megaloblastic anemia. *Primidone* - **Primidone** is an antiepileptic drug that is metabolized to **phenobarbitone** and phenylethylmalonamide (PEMA). - Like phenobarbitone, it is an **hepatic enzyme inducer** and can therefore **interfere with folic acid metabolism**. *Phenytoin* - **Phenytoin** is a well-known antiepileptic drug that often causes **folate deficiency**. - It interferes with folate metabolism by **inhibiting intestinal folate absorption** and by increasing its breakdown through enzyme induction.

Q: Suxamethonium is available as a clear, colourless aqueous solution. What is the shelf life of suxamethonium when stored correctly?

2 years. ***2 years*** - When **stored correctly** (refrigerated between 2-8°C and protected from light), the typical shelf life of suxamethonium is **2 years**. [1] - This stability ensures its effectiveness as a **neuromuscular blocking agent** when needed for medical procedures. [1] *6 months* - A 6-month shelf life is generally too short for the refrigerated, unopened vials of **suxamethonium** from the manufacturer. - This period is more commonly associated with the stability of certain reconstituted or diluted medications. *1 year* - While some medications might have a 1-year shelf life, **suxamethonium** typically has a longer stability period when stored under optimal conditions. - A 1-year shelf life would be relatively short for an unopened, stock solution of this drug. *3 years* - A 3-year shelf life is generally considered too long for **suxamethonium** under standard refrigerated storage conditions. - Most manufacturers specify a 2-year shelf life to maintain drug efficacy and safety.

Q: Which of the following describes the type of measles vaccine used in immunization?

It is a live attenuated vaccine.. ***It is a live attenuated vaccine.*** - The **measles vaccine** contains a weakened form of the measles virus, allowing it to replicate in the body without causing disease. - This type of vaccine elicits a strong, **long-lasting immune response** resembling natural infection. - Live attenuated vaccines are preferred for measles because they provide superior cellular and humoral immunity compared to inactivated vaccines. *It provides lifelong immunity.* - While the measles vaccine provides **long-lasting and robust immunity**, it is not always lifelong for everyone, and a second dose is recommended to ensure maximal protection. - Immunity can wane over time in some individuals, making them susceptible to infection. - This describes the vaccine's **effectiveness**, not its type or composition. *The vaccine is given in two doses.* - The standard measles vaccination schedule involves **two doses**, typically given as part of the MMR (measles, mumps, rubella) vaccine. - This describes the **administration protocol**, not the vaccine type itself. *The vaccine is typically administered at 12 months of age.* - The **first dose** of the measles vaccine (MMR) is commonly administered between **12 and 15 months of age**, with the second dose between 4 and 6 years. - This timing describes the **administration schedule**, not the vaccine type or composition.

Q: What is the primary mechanism by which steroids exert their anti-inflammatory action?

Phospholipase A2. ***Phospholipase A2*** - Steroids exert their primary anti-inflammatory action by inducing the synthesis of **lipocortin-1 (annexin-1)**, which then inhibits **phospholipase A2 (PLA2)**, an enzyme crucial for the release of **arachidonic acid** from cell membrane phospholipids. - By blocking PLA2, steroids prevent the formation of all subsequent inflammatory mediators derived from arachidonic acid, including **prostaglandins**, **leukotrienes**, and **thromboxanes**. - This represents the most **upstream** mechanism of steroid anti-inflammatory action, affecting multiple downstream pathways simultaneously. *Cyclooxygenase* - **Cyclooxygenase (COX)** enzymes, specifically COX-1 and COX-2, are responsible for converting arachidonic acid into **prostaglandins** and **thromboxanes**. - While steroids ultimately reduce COX activity by limiting substrate availability, their direct and primary inhibition is not on COX itself but at an earlier step in the inflammatory cascade. *Lipoxygenase* - The **lipoxygenase (LOX)** pathway converts arachidonic acid into **leukotrienes**, which are potent mediators of inflammation, particularly in asthma and allergic reactions. - Steroids do inhibit the formation of leukotrienes indirectly by blocking their precursor, arachidonic acid, but their direct target is not LOX itself. *Myeloperoxidase* - **Myeloperoxidase** is an enzyme found primarily in **neutrophils** and macrophages, playing a role in oxidative stress and microbial killing by producing hypochlorous acid (bleach). - While steroids can modulate immune cell function, their direct anti-inflammatory mechanism is not through the inhibition of myeloperoxidase activity.

Q: What does the therapeutic index of a drug signify?

Safety margin. ***Safety margin*** - The **therapeutic index (TI)** is a ratio comparing the dose that produces a toxic effect (TD50 or LD50) to the dose that produces a therapeutically desired effect (ED50) [1]. - A higher therapeutic index indicates a **wider safety margin**, meaning there is a greater difference between the effective and toxic doses [1, 2].*Dose which produces maximum effect* - This describes the **efficacy** of a drug at its maximal point, not its therapeutic index. - The therapeutic index is concerned with the range of doses that can be safely given to achieve a therapeutic effect [2].*Efficacy* - **Efficacy** refers to the maximum effect a drug can produce regardless of the dose. - The therapeutic index is a measure of drug safety, not primarily its efficacy [1].*Maximum response that can be elicited by a drug* - This definition also describes the **efficacy** or **maximal effect** of a drug. - The therapeutic index quantifies the **ratio of toxic to effective doses**, providing insight into safety [1].

Q: All of the following are adverse effects of glucocorticoids except:

Hypoglycemia. ***Hypoglycemia*** - Glucocorticoids are known to **increase blood glucose levels** by promoting gluconeogenesis and glycogenolysis, thus they cause **hyperglycemia**, not hypoglycemia. - They also induce **insulin resistance**, further contributing to elevated blood sugar. *Cataract* - Long-term use of high-dose glucocorticoids can cause **posterior subcapsular cataracts** due to metabolic changes in the lens. - This is a well-recognized ocular side effect of corticosteroids. *Peptic ulcer* - Glucocorticoids can impair the **gastric mucosal barrier**, increase acid secretion, and reduce prostaglandin synthesis, leading to an increased risk of **peptic ulcers**. - This effect is potentiated when used concurrently with NSAIDs. *Infections* - Glucocorticoids are **immunosuppressive**, reducing the body's ability to fight off pathogens. - This increases susceptibility to various infections, including bacterial, viral, fungal, and opportunistic infections.

Q: Therapeutic index of a drug is an indicator of its:

Safety Profile. ***Safety Profile*** - The **therapeutic index (TI)** is a ratio that compares the dose of a drug that produces a **toxic effect** to the dose that produces a **therapeutically desired effect**. - A higher therapeutic index generally indicates a **safer drug**, as it means a larger dose is required to cause toxic effects compared to the therapeutic dose. *Effectiveness* - While related to efficacy, effectiveness usually refers to how well a drug works in **real-world clinical practice**, not directly measured by the therapeutic index. - The therapeutic index focuses on the **margin between efficacy and toxicity**, rather than just the degree of positive response. *Adverse Effects* - The **therapeutic index** considers the toxic dose, which leads to adverse effects, but it's a measure of the **margin of safety**, not just the presence or absence of adverse effects. - It quantifies the **risk of adverse effects** relative to the therapeutic benefit, rather than simply listing or describing them. *Therapeutic Effect* - The **therapeutic index** incorporates the dose required for a therapeutic effect, but its primary purpose is to assess the **risk of toxicity** in relation to that therapeutic effect. - It's a measure of the **balance between benefit and harm**, not solely the therapeutic benefit itself.

Question 1

Which of the following statements is true about atosiban?

Accepted Answer

is an oxytocin receptor antagonist

Answer

is least effective in inhibiting preterm uterine contractions

Answer

is a progesterone receptor antagonist

Answer

acts primarily on beta-adrenergic receptors

Question 2

What is the classification of Sumatriptan?

Accepted Answer

5HT 1B/1D agonist

Answer

5HT 1D antagonist

Answer

5HT 1A antagonist

Answer

5HT 1 agonist

Question 3

Hypercalcemia is caused by all except:

Accepted Answer

Loop diuretics

Answer

Lithium

Answer

Thiazides

Answer

Vitamin D intoxication

Question 4

Which one of the following drugs does not interfere with folic acid metabolism?

Accepted Answer

Gabapentin

Answer

Phenobarbitone

Answer

Primidone

Answer

Phenytoin

Question 5

Suxamethonium is available as a clear, colourless aqueous solution. What is the shelf life of suxamethonium when stored correctly?

Accepted Answer

2 years

Answer

1 year

Answer

3 years

Answer

6 months

Question 6

Which of the following describes the type of measles vaccine used in immunization?

Accepted Answer

It is a live attenuated vaccine.

Answer

The vaccine is given in two doses.

Answer

It provides lifelong immunity.

Answer

The vaccine is typically administered at 12 months of age.

Question 7

What is the primary mechanism by which steroids exert their anti-inflammatory action?

Accepted Answer

Phospholipase A2

Answer

Myeloperoxidase

Answer

Cyclooxygenase

Answer

Lipoxygenase

Question 8

What does the therapeutic index of a drug signify?

Accepted Answer

Safety margin

Answer

Dose which produces maximum effect

Answer

Efficacy

Answer

Maximum response that can be elicited by a drug

Question 9

All of the following are adverse effects of glucocorticoids except:

Accepted Answer

Hypoglycemia

Answer

Peptic ulcer

Answer

Infections

Answer

Cataract

Question 10

Therapeutic index of a drug is an indicator of its:

Accepted Answer

Safety Profile

Answer

Effectiveness

Answer

Adverse Effects

Answer

Therapeutic Effect

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?